Myotonic Dystrophy clinical trials at UCSD
1 research study open to eligible people
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
open to eligible people ages 18-70
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogeneity going forward. Funding Source- FDA OOPD
La Jolla, California and other locations
Our lead scientists for Myotonic Dystrophy research studies include Chamindra Konersman, MD.
Last updated: